Skip to main content
SpringerLink
Log in

Lipid Lowering Therapy

  • Chapter
Contemporary Concepts in Cardiology

Part of the book series: Developments in Cardiovascular Medicine ((DICM,volume 217))

  • 92 Accesses

Abstract

Prevention of coronary heart disease is not only important from the public health point of view. Efforts to prevent disease test our fundamental concepts of etiology. Atherosclerotic coronary heart disease is a complex process of atherosclerotic plaque accumulation and interaction with a thrombotic and fibrinolytic system, which may or may not ultimately result in a clinical syndrome. Because of the slowness and complexity of this lifelong process, preventive interventions may as well seem too weak or too slow in their power to appreciably alter the course of clinical disease. The societal burden of this disease, however, has become so great and its treatment so technologically complex, that even small gains in its prevention applied to large populations can be appreciable in terms of both reduction in human suffering and reduction in health care expenditures.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 299.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 379.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 379.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Keys A, et al. Coronary heart disease in seven countries. Circulation. 1970;41(Suppl I): I–1

    Google Scholar 

  2. Keys Ansel. Seven Countries: A Multivariate Analysis of Death and Coronary Heart Disease. Cambridge,Mass: Harvard University Press, 1980

    Google Scholar 

  3. Robertson TL, et al. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii, and California. Incidence of myocardial infarction and death from coronary heart disease. Amer J Cardiol. 1977;39: 239.

    Article  PubMed  CAS  Google Scholar 

  4. Kannel WB, et al. Risk factors in coronary heart disease. An evaluation of several serum lipids as predictors of coronary heart disease-The Framingham Study. Ann Int Med. 1964;61: 888.

    PubMed  CAS  Google Scholar 

  5. Castelli WP. Cardiovascular disease and multifactorial risk: challenge of the 1980’s. Am Heart J. 1983;106: 1191.

    Article  PubMed  CAS  Google Scholar 

  6. Cornfield J. Joint dependence of risk of coronary heart disease on serum cholesterol and systolic pressure: A discriminant function analysis. Fed Proc. 1962;21 (part 2): 58.

    PubMed  Google Scholar 

  7. Gordon T, et al. High density lipoprotein as a protective factor againt coronary heart disease. Am J Med. 1977;62: 707.

    Article  PubMed  CAS  Google Scholar 

  8. Castelli WP, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels, The Framingham Study. JAMA. 1986;256: 2835.

    Article  PubMed  CAS  Google Scholar 

  9. Abbott RD, et al. High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction. The Framingham Study. Arteriosclerosis. 1988;8: 207.

    Article  PubMed  CAS  Google Scholar 

  10. Stamler J, Wentworth D, Neaton JD, MRFIT Research Group. Is the relationship between cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in the 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986;256: 2823.

    Article  PubMed  CAS  Google Scholar 

  11. Lipid Research Clinics Program. The Lipids Research Clinics Coronary Primary Prevention Trial results I. Reduction in incidence of coronary heart disease. JAMA. 1984;251: 351.

    Article  Google Scholar 

  12. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial Results II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251: 365.

    Article  Google Scholar 

  13. Frick MH, et al. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middLe-aged men with dyslipidemia. N Engl J Med. 1987;317: 1237.

    Article  PubMed  CAS  Google Scholar 

  14. Manninen V, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA. 1988;260: 641.

    Article  PubMed  CAS  Google Scholar 

  15. Manninen V, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation. 1992;85: 37.

    Article  PubMed  CAS  Google Scholar 

  16. Frick MH, et al. Gemfibrozil and coronary heart disease. N Engl J Med. 1988;318: 1275.

    Article  Google Scholar 

  17. Law MR, Thompson SG, Wald NJ. Assessing possible hazards of reducing serum cholesterol. BMJ. 1994;308: 373.

    Article  PubMed  CAS  Google Scholar 

  18. Davey-Smith G, Song F, Sheldon TA. Cholesterol lowering and mortality: the importance of considering initial level of risk. BMJ. 1993;306: 1367.

    Article  Google Scholar 

  19. Expert Panel. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA. 1993;269: 3015.

    Article  Google Scholar 

  20. Arntzenius AC, et al. Diet, lipoproteins, and the progression of coronary atherosclerosis. The Leiden Intervention Trial. N Engl J Med. 1985;312: 805.

    Article  PubMed  CAS  Google Scholar 

  21. Ornish D, et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet. 1990;336: 129.

    Article  PubMed  CAS  Google Scholar 

  22. Ornish D, et al. Can lifestyle changes reverse coronary atherosclerosis? Four year results of the Lifestyle Heart Trial. Circulation. 1993;88 (Suppl 4): I–385

    Google Scholar 

  23. Watts GF, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St. Thomas’ Atherosclerosis Regression Study STARS. Lancet. 1992;339: 563.

    Article  PubMed  CAS  Google Scholar 

  24. Levy RI, et al. The influence of changes in lipid values induced by cholestyramine and diet on the progression of coronary artery disease: results of the NHLBI Type II Coronary Intervention Study. Circulation. 1984;69: 325.

    Article  PubMed  CAS  Google Scholar 

  25. Blankenhorn DH, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257: 3233.

    Article  PubMed  CAS  Google Scholar 

  26. Waters D, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation. 1994;89: 959.

    Article  PubMed  CAS  Google Scholar 

  27. Blankenhorn DH, et al. Coronary angiographic changes with lovastatin therapy: The Monitored Atherosclerosis Regression Study (MARS). Ann Int Med. 1993;119: 969.

    PubMed  CAS  Google Scholar 

  28. Brown G, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323: 1289.

    Article  PubMed  CAS  Google Scholar 

  29. Stewart BF, et al. Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol. J Am Coll Cardiol. 1994;23: 899.

    Article  PubMed  CAS  Google Scholar 

  30. Moore RB, Frantz ID, Buchwald H. Changes in cholesterol pool size, turnover rate, and fecal bile acid and sterol excretion after partial ileal bypass in hypercholesterolemic patients. Surgery. 1969;65: 98.

    PubMed  CAS  Google Scholar 

  31. Buchwald H, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. N Engl J Med. 1990;323: 946.

    Article  PubMed  CAS  Google Scholar 

  32. Buchwald H, et al. Changes in sequential coronary arteriograms and subsequent coronary events. JAMA. 1992;268: 1429.

    Article  PubMed  CAS  Google Scholar 

  33. Kane JP, et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA. 1990;264: 3007.

    Article  PubMed  CAS  Google Scholar 

  34. M.A.A.S.Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet. 1994;344: 633.

    Article  Google Scholar 

  35. Hashell WL, et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). Circulation. 1994;89: 975.

    Article  Google Scholar 

  36. Pitt B, et al. Design and recruitment in the United States of a multicenter quantitative angiographic trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC I). Am J Cardiol. 1993;72: 31.

    Article  PubMed  CAS  Google Scholar 

  37. Pitt B, et al. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I). J Amer Coll Cardial. 1994;23 (special issue): 131A

    Google Scholar 

  38. Furberg CD, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation. 1994;90: 1679.

    Article  PubMed  CAS  Google Scholar 

  39. Howard G, et al. Carotid artery intimal-medial thickness distribution in general populations as evaluated by B-mode ultrasound. Stroke. 1993;24: 1297.

    Article  PubMed  CAS  Google Scholar 

  40. Crouse JR, et al. Pravastatin, lipids and atherosclerosis in the carotid arteries (PLAC II). Am J Cardiol. 1995;75: 455.

    Article  PubMed  Google Scholar 

  41. Furberg CD, et al. Pravastatin, lipids, and major coronary events. Am J Cardiol. 1994;73: 1133.

    Article  PubMed  CAS  Google Scholar 

  42. Waters D, Craven TE, Lesperance J. Prognostic significance of progression of coronary atherosclerosis. Circulation. 1993;87: 1067.

    Article  PubMed  CAS  Google Scholar 

  43. Brown BG, et al. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 1993;87: 1781.

    Article  PubMed  CAS  Google Scholar 

  44. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344: 1383.

    Google Scholar 

  45. The Pravastatin Multinational Study Group for Cardiac Risk Patients. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200-300 mg/dL) plus two additional atherosclerotic risk factors. Am J Cardiol. 1993;72: 1031.

    Google Scholar 

  46. Castelli WP. The triglyceride issue: A view from Framingham. Am Heart J. 1986; 112: 432.

    Article  PubMed  CAS  Google Scholar 

  47. Bengtsson C, et al. Associations of serum lipid concentrations and obesity with mortality in women: 20 year follow up of participants in prospective population study in Gottenburg, Sweden. BMJ. 1993;307: 1385.

    Article  PubMed  CAS  Google Scholar 

  48. Criqui M, et al. Plasma triglyceride level and mortality from coronary heart disease. N Engl J Med. 1993;328: 1220.

    Article  PubMed  CAS  Google Scholar 

  49. Reaven GM. Role of insulin resistance in human disease, Banting Lecture 1988. Diabetes. 1988;37: 1595.

    Article  PubMed  CAS  Google Scholar 

  50. Haffner SM, et al. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes. JAMA. 1990;263: 2893.

    Article  PubMed  CAS  Google Scholar 

  51. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb. 1991;11: 2.

    Article  PubMed  CAS  Google Scholar 

  52. NIH Consensus Development Panel. NIH Consensus conference: triglyceride, high-density lipoprotein, and coronary heart disease. JAMA. 1993;269: 505.

    Article  Google Scholar 

  53. Abbott RD, Carroll FR. Interpreting multiple logistic regression coefficients. Am J Epidemiol. 1984;119: 830.

    PubMed  CAS  Google Scholar 

  54. Blankenhorn DH, et al. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts: Lipid and nonlipid factors. Circulation. 1990;81: 470.

    Article  PubMed  CAS  Google Scholar 

  55. Mahley RW, Rall SC, Jr. Type III Hyperlipoproteinemia (Dysbeta lipoproteinemia): The role of apolipoprotein E in normal and abnormal lipoprotein metabolism. New York: Mc-Graw Hill, 1995.1953.

    Google Scholar 

  56. Goldstein JL, et al. Hyperlipidemia in coronary heart disease: II. Genetic analysis in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest. 1973;52: 1544.

    Article  PubMed  CAS  Google Scholar 

  57. Brunzell JD, et al. Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia. J Lipid Res. 1983;24: 147.

    PubMed  CAS  Google Scholar 

  58. Austin MA, et al. Low density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988;260: 1917.

    Article  PubMed  CAS  Google Scholar 

  59. Austin MA, et al. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation. 1990;82: 495.

    Article  PubMed  CAS  Google Scholar 

  60. Austin MA. Genetics of low-density lipoprotein subclasses. Curr Opin Lipidol. 1993;4: 125.

    Article  CAS  Google Scholar 

  61. Austin MA, et al. Inheritance of low density lipoprotein subclass patterns in familial combined hyperlipidemia. Arteriosclerosis. 1990; 10: 520.

    Article  PubMed  CAS  Google Scholar 

  62. Hokanson JE, et al. Plasma triglyceride and LDLheterogenety in familial combined hyperlipidemia. Arterioscler Thromb. 1993;13: 427.

    Article  PubMed  CAS  Google Scholar 

  63. Simpson HCR, et al. Hypertriglyceridemia and hypercoagulability. Lancet. 1983; 1: 786.

    Article  PubMed  CAS  Google Scholar 

  64. Hamsten A, et al. Increased levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med. 1985;313: 1557.

    Article  PubMed  CAS  Google Scholar 

  65. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231: 360.

    Article  Google Scholar 

  66. Canner PL, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. JACC. 1986;8: 1245.

    PubMed  CAS  Google Scholar 

  67. Small DM, et al. Physicochemical and histological changes in the arterial wall of non-human primates during progression and regression of atherosclerosis. J Clin Invest. 1984;73: 1590.

    Article  PubMed  CAS  Google Scholar 

  68. Armstrong ML, Megan MB. Arterial fibrous proteins in cynomologous monkeys after atherogenic and regression diets. Circ Res. 1975;36: 256.

    Article  PubMed  CAS  Google Scholar 

  69. Armstrong ML, Megan MB. Lipid depletion in atheromatous coronary arteries in rhesus monkeys after regression diets. Circ Res. 1972;30: 675.

    Article  PubMed  CAS  Google Scholar 

  70. Vartiainen I, Kanerva K. Arteriosclerosis and war-time. Ann Med Intern Fenn. 1947;36: 748.

    PubMed  CAS  Google Scholar 

  71. Strom A, Jensen RA. Mortality from circulatory diseases in Norway 1940-1945. Lancet. 1951;126.

    Google Scholar 

  72. Richardson PD, Davies MJ, Born GVR. Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet. 1989;11: 941.

    Article  Google Scholar 

  73. Davies MJ. A macro and micro view of coronary vascular insult in isechemic heart disease. Circulation. 1990;82 (Supp II): II–38

    Google Scholar 

  74. Fernandez-Ortiz A, et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. JACC. 1994;23: 1562.

    PubMed  CAS  Google Scholar 

  75. Treasure CB, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 1995;332: 481.

    Article  PubMed  CAS  Google Scholar 

  76. Gould KL, et al. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by position emission tomography after dipyridamole in patients with coronary disease. Circulation. 1994;89: 1530.

    Article  PubMed  CAS  Google Scholar 

  77. Scanu AM. Lipoprotein (a)-A genetic risk factor for premature coronary heart disease. JAMA. 1992;267: 3326.

    Article  PubMed  CAS  Google Scholar 

  78. Badimon JJ, et al. Platelet deposition at high shear rates is enhanced by high plasma cholesterol levels. In vivo study in the rabbit model. Arterioscler Thromb. 1991;11: 395.

    Article  PubMed  CAS  Google Scholar 

  79. L-Lacoste L, et al. Pravachol decreases thrombus formation in hypercholesterolemic coronary patients in conjunction with improvements in serum lipids. JACC. 1994;23(special Issue): 131A.

    Google Scholar 

  80. Shah PK, et al. Human monocyte-derived macrophages express collagenase and induce collagen breakdown in atherosclerotic fibrous caps: implications for plaque rupture. Circulation. 1993;88: I–254.

    Google Scholar 

Download references

Authors
  1. Donald A. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer Science+Business Media New York

About this chapter

Cite this chapter

Smith, D.A. (1999). Lipid Lowering Therapy. In: Contemporary Concepts in Cardiology. Developments in Cardiovascular Medicine, vol 217. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5007-5_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-5007-5_4

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7274-5

  • Online ISBN: 978-1-4615-5007-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation